Cardiologicum Hamburg

Hamburg 22041

1 studies enrolling now · 8 studies all time

What they study most

Atherosclerotic Cardiovascular Disease (ASCVD), Atrial Fibrillation, Cardiovascular Disease, Coronary Heart Disease (CHD), Elevated Lp(a), Lipoprotein Disorder, Percutaneous Coronary Intervention, Prevention of Stroke or Systemic Embolism

Studies at this site

• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) — Recruiting now
• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) — Running, not enrolling
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke — Completed
• A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)] — Completed
• A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke — Stopped early
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI) — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early